The EU has approved Janssen-Cilag’s schizophrenia drug Xeplion.
Positive results in placebo-controlled trials have convinced the European Commission to grant approval for the antipsychotic injection.
Xeplion is now marketable within Europe as maintenance therapy for adult patients stabilied on risperidone or paliperidone.
This represents a promising new therapy option for a condition which is estimated to affect around one in every 100 people.
Dr Christophe Tessier, medical affairs director for psychiatry atJanssen in Europe, said that Xeplion gives medical professionals an “opportunity to rethink their approach” to treating schizophrenia.
Schizophrenia is estimated to affect about one in every 100 people.